Market Performance - In July, the A-share market experienced an overall upward trend, with the Shanghai Composite Index rising by 3.74%, the Shenzhen Component Index increasing by 5.20%, and the ChiNext Index gaining 8.14% by the end of July [1] Top Performing Stocks - The top-performing stock in July was Shangwei New Materials, which saw a staggering increase of 1083.42%, making it the first stock in A-shares to achieve a tenfold increase since 2025 [3][6] - Guangshengtang ranked second with a monthly increase of 218.94%, driven by significant progress in its hepatitis B innovative drug development [3][7] - Hengli Drilling Tools achieved a monthly increase of 191.24%, boosted by the commencement of a major hydropower project in the Yarlung Tsangpo River basin [3][9] Individual Stock Highlights - **Shangwei New Materials**: The stock price surged from 9.34 yuan to 92.07 yuan between July 9 and July 30, with 11 trading days experiencing a 20% limit up. The surge was attributed to an announcement regarding a significant acquisition that would change its controlling shareholder [6] - **Guangshengtang**: The company received ethical review approval for its phase III clinical trial of GST-HG141 and had another drug, GST-HG131, recognized as a breakthrough therapy by the National Medical Products Administration [7][8] - **Hengli Drilling Tools**: The company specializes in manufacturing various engineering drilling tools and benefited from the positive sentiment surrounding the hydropower sector following the announcement of a large-scale project [9]

Market Overview - In July, the A-share market experienced an overall upward trend, with the Shanghai Composite Index rising by 3.74%, the Shenzhen Component Index increasing by 5.20%, and the ChiNext Index gaining 8.14% by the end of July [1] Top Performing Stocks - The top-performing stock in July was Shangwei New Materials, which saw a staggering increase of 1083.42%, making it the first stock to achieve a tenfold increase in A-shares since 2025 [3][6] - Guangshengtang ranked second with a monthly increase of 218.94%, driven by significant progress in its hepatitis B innovative drug development [3][7] - Hengli Drilling Tools achieved a monthly increase of 191.24%, boosted by the commencement of a major hydropower project in the Yarlung Tsangpo River basin [3][9] Detailed Stock Performance - **Shangwei New Materials**: - The stock price surged from 9.34 yuan to 92.07 yuan between July 9 and July 30, with 11 trading days experiencing a 20% limit up [6] - The surge was attributed to an announcement regarding a significant acquisition that would change the controlling shareholder [6] - The company reported a net profit of 88.68 million yuan for 2024, a year-on-year increase of 25.01% [6] - **Guangshengtang**: - The stock had two trading days with a 20% limit up, with a total increase of 218.94% for the month [7] - The company received ethical review approval for its phase III clinical trial of GST-HG141 and had another drug, GST-HG131, recognized as a breakthrough therapy [7][8] - Guangshengtang has been a key player in the antiviral and liver disease sectors for over 20 years [8] - **Hengli Drilling Tools**: - The stock experienced three trading days with a 30% limit up, culminating in a 191.24% increase for the month [9] - The rise was linked to the launch of a significant hydropower project with an investment of approximately 1.2 trillion yuan [9] - Hengli specializes in the research, manufacturing, and sales of various drilling tools for construction projects [9]